In the present study, the receptor binding potential oftransferrin (Tf) was linked to an antibody binding specificity. Human Tf was fused to mouse-human chimeric IgG3 at three positions: at the end of heavy chain constant region 1 (CHi), after the hinge, and after CH3. The resulting Tf-antibody fusion proteins were able to bind antigen and the Tf receptor. The CH3-Tf fusion protein showed no complement-mediated cytolysis but possessed IgG receptor I (Fc'yRI) Morbidity caused by brain dysfunction affects more than 50 million persons in the United States. Although various neuropharmaceutical drugs have the potential for treating specific brain diseases, their effective delivery remains a problem. In vivo drug delivery to the brain is limited by poor transport of water-soluble drugs through the brain capillary endothelial wall that makes up the blood-brain barrier (BBB). Brain capillary endothelial tight junctions form a very highresistance barrier to the uptake of circulating solutes (1, 2).
Morbidity caused by brain dysfunction affects more than 50 million persons in the United States. Although various neuropharmaceutical drugs have the potential for treating specific brain diseases, their effective delivery remains a problem. In vivo drug delivery to the brain is limited by poor transport of water-soluble drugs through the brain capillary endothelial wall that makes up the blood-brain barrier (BBB). Brain capillary endothelial tight junctions form a very highresistance barrier to the uptake of circulating solutes (1, 2) .
There are many possible strategies for drug delivery to the brain. Disruption of the BBB by hyperosmolar shock (3) or by the administration of vasoactive substances such as leukotrienes (4) provides transient access to the brain. However, this approach allows uncontrolled access of blood-borne compounds to the brain, and when the BBB is repetitively opened, neuropathologic changes take place in the brain (5) . Direct intraventricular administration of drug by using surgical techniques provides another approach (6) . However, intraventricularly administered drugs are distributed primarily to the surface of the brain, and penetration into the parenchyma is limited by diffusion (7) . In addition, the drug will be rapidly removed from the intraventricular space by cerebrospinal fluid bulk flow. Peptide lipidization, which involves the attachment of lipid-soluble moieties, has been useful for small peptides (8) but does not appear useful for peptides of >5 amino acids (7) . Liposomes, a standard approach to drug delivery, are too large to traverse the BBB and have not proved to be effective as neuropharmaceutical drug delivery vehicles for the brain (7) .
Specific receptors on the BBB are used to transport required nutrients and growth factors such as insulin (9) , transferrin (Tf) (10) , and insulin-like growth factors (11) from the blood to the brain. These receptors provide potential avenues for transport into the brain. For example, immunoglobulin molecules are normally excluded from the brain (12) ; however, an antibody to the Tf receptor (TfR) has been shown to be transported into the brain parenchyma and to be effective as a drug delivery vehicle (13) .
In the present study, we have used the ligands to the brain endothelial receptors, instead of an anti-receptor antibody, to direct molecules to the brain and have constructed proteins consisting of Tf fused to antibody. Tf was chosen as the receptor-targeting ligand because TfRs are abundant on the vascular endothelium of the brain capillaries (14) . Antibodies were chosen because their binding specificity can be used either for delivery of agents to the brain or for secondary targeting once the fusion protein is within the brain. Fusion proteins consisting of human Tf sequences fused to the C terminus of full-length and truncated antibody sequences were constructed and found to retain both antigen and TfR binding activity. Additionally, depending on where the Tf is joined to the antibody, molecules were produced that retain some of the antibody effector functions. Our results show that Tf can indeed be used to target fusion proteins to the brain.
MATERIALS AND METHODS
Cell Lines. The human histiocytic lymphoma U937, which expresses Fc and C3 receptors (15, 16) , was grown in RPMI 1640 medium with 10% (vol/vol) fetal calf serum. Sp2/0 and P3X63Ag8.653 cells were cultured in Iscove's modified Dulbecco's medium with 5% (vol/vol) calf serum.
Construction and Characterization of the IgG3-Tf Fusion Proteins. Site-directed mutagenesis was used to generate unique restriction enzyme cleavage sites in the human IgG3 heavy chain gene as described (17, 18) . The human Tf cDNA was cloned at the 3' end of the heavy chain constant region 1 (CH1) exon (CH1-Tf), immediately after the hinge (H) (H-Tf) (17) , or at the 3' end of the CH3 exon (CH3-Tf) in the mouse-human IgG3 heavy chain gene specific for the hapten dansyl (DNS, 5-dimethylaminonaphthalene-1-sulfonyl) (18) . The IgG3-Tf fusion heavy chain gene and the chimeric mousehuman K light chain specific for DNS (pSV184AHneo) (19, 20) were transfected into P3X63Ag8.653 or Sp2/0 by electroporation, transfectomas were selected, and those producing the fusion proteins were identified as described (21 
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Proc. Natt Acad Sci USA 92 (1995) 2821 ducing the IgG3-Tf fusion proteins were biosynthetically labeled with [35S]methionine, and the proteins were immunoprecipitated and analyzed by SDS/PAGE with or without 2-mercaptoethanol. The IgG3-Tf fusion proteins were purified from culture supernatants by affinity column chromatography (22) . Purity was determined by Coomassie blue staining of SDS/PAGE.
Receptor Binding Assays. IgG receptor I (FcyRI) binding was assayed essentially as described (23) with U937 cells. TfR was purified from freshly obtained full-term human placentas (24) by affinity chromatography on a human Tf-Sepharose column. The resulting receptor was 98% pure and of the expected molecular weight. The relative affinity of the various fusion proteins for the TfR was estimated by a solid-phase competition assay on microtiter plates coated with TfR incubated with a mixture of 4 nM 125I-labeled Tf and various concentrations of unlabeled competitor (100 ,ul per well). Bound radioactivity was determined by using a y counter. Nonlinear curve fitting to determine 50% inhibition points was performed by using SIGMA PLOT.
Capillary Depletion. Capillary depletion experiments were performed essentially as described (13) . Fusion proteins were labeled with [3H]succinimidyl propionate and the control IgG was labeled with [14C]acetic anhydride. For all experiments, the radiolabeled compounds were injected as a 400-,ul bolus into the tail vein of female Sprague-Dawley rats (100-125 g) under halothane anesthesia, and the animals were sacrificed at the appropriate time by using a lethal dose of anesthetic. Radiolabeled IgG was coinjected with the labeled fusion protein to serve as a control for nonspecific radioactivity recovered in the brain due to residual blood. All data were corrected for residual blood in the brain by using the coinjected 14C-labeled chimeric IgG3 as a blood marker. Data are expressed as the percent of the injected dose in the parenchyma or capillary fractions.
Internal Carotid Artery Perfusion. CH3-Tf (40 ,ug) iodinated by the chloramine T method was used within 24 hr for internal carotid artery perfusion with male Sprague-Dawley rats (300-325 g) as described (25) . Non-redluced perfusate at a rate of 3.8 ml/min. Perfusate consisted of Krebs-Henselite buffer (KHB, pH 7.4) in an atmosphere of 95% 02/5% C02, containing bovine serum albumin (BSA) at 0.1 g/dl and 125I-labeled CH3-Tf at 5 ACi/ml (1 Ci = 37 GBq).
At the end of the 5-min perfusion, the cerebral blood volume was cleared by cerebral perfusion with KHB containing 5% BSA at the rate of 3.5 ml/min for 60 sec. The animal was decapitated, and the brain was removed, weighed, and homogenized in a tissue grinder in 5 vol of ice-cold 0.05 M Tris HCl, pH 7.4/1 mM EDTA/1% Triton X-100. Radiolabeled transported proteins immunoprecipitated from the supernatant of brain homogenates with DNS-Sepharose and subsequently with protein G-agarose were analyzed by the SDS/PAGE.
RESULTS
Transfection and Characterization of the IgG3-Tf Fusion Proteins. In an attempt to create a family of molecules for use in targeting across the BBB, an antibody combining site was joined to Tf. Cloning cassettes were constructed such that Tf could be joined at various positions to human IgG3. Human IgG3 was chosen for use as the immunoglobulin since its extended hinge region of 62 amino acids should provide spacing and flexibility, thereby facilitating simultaneous antigen and receptor binding. Transfectomas secreting the fusion heavy chain and the anti-DNS were expanded for further characterization (21) . These transfectomas secreted up to 10 jig of chimeric protein per 106 cells per 24 hr. The biosynthetically labeled secreted IgG3-Tf fusion proteins were immunoprecipitated with DNS-BSA-conjugated Sepharose beads, demonstrating that they retained the ability to react with their specific antigen. SDS/PAGE analysis ( (Fig. 1 C) were identical except for H-Tf, which was predominantly (Fab')2, presumably due to formation of inter-heavy-chain disulfide bonds during storage.
Effector Functions and Receptor Binding of the CH3-Tf Fusion Proteins. Fusion proteins that contain the entire Fc portion of the antibody may retain the effector functions associated with the IgG molecule. One effector function is complement activation. Although unable to carry out complement-mediated hemolysis of antigen-coated sheep red blood cells (SRBCs) (Fig. 2A) , CH3-Tf did consume complement in an antigen-dependent manner but not as effectively as chimeric IgG3 (Fig. 2B) . Moreover, CH3-Tf binds Clq as well as wild-type IgG3 (Fig. 2C) IgG3 affects subsequent steps in the activation cascade. IgG4, which does not bind Clq and activate complement, was included as a negative control.
Human IgG3 binds to the Fc'yRI receptor through determinants located in the CH2 domain. Both unlabeled chimeric IgG3 and the CH3-Tf inhibited the binding of 125I-labeled IgG3 to the FcyRI receptors present on interferon-y-treated U937 cells with 50% inhibition occurring at 10 nM IgG3 and 3.5 nM CH3-Tf (Fig. 3A) . Therefore, under these assay conditions CH3-Tf was slightly more effective than IgG3 in the inhibition of 125I-labeled IgG3 binding to FcyRI.
A critical question regarding the Tf fusion proteins is whether they retain TfR binding activity. Both unlabeled human Tf and the IgG3-Tf chimeric fusion proteins were able to compete with 125I-labeled Tf for binding to purified human placental TfR immobilized on microtiter plates (Fig. 3B) (27) . After incubation, hemolysin-sensitized 51Cr-loaded SRBCs were added, incubation was continued for 45 min, and the unlysed SRBCs were pelleted. The supernatants were collected and radioactivity was measured in a -y counter. (C) Clq binding was determined using a solid-phase ELISA (27 Proc. Natt Acad ScL USA 92 (1995) loProc. Natl. Acad. Sci. USA 92 (1995) 2823 renchyma, as a function of time, it is possible to determine whether the protein has traversed the BBB.
Our results indicate that the ability to cross the BBB depends on the structure of the fusion protein, though there was some variability in maximum uptake among different preparations of the same fusion protein. Among the fusion proteins, H-Tf achieved the highest level in the brain with 0.3% of the injected dose appearing in the parenchyma (Fig.  4A ). H-Tf was rapidly taken up with a maximum seen in the brain at the earliest time point 15 min after injection, but with radioactivity persisting for 24 hr (Fig. 4B) . CH3-Tf is less effective with -0.15% of the injected dose entering the brain parenchyma; CH1-Tf has the lowest affinity for the TfR with only -0.1% of the injected dose entering the brain. Chimeric IgG3 was not significantly targeted to the brain parenchyma and 14C-labeled chimeric IgG3 was used as an internal control to correct all data for blood contamination. Tf targeted to the brain less efficiently than the fusion proteins with <0.1% of the injected dose recovered in the brain parenchyma.
Recovery experiments were undertaken to confirm that the radioactivity measured in the brain parenchyma represented intact fusion protein. Proteins were iodinated to obtain sufficient radioactivity, although iodination to high specific activity resulted in significant fragmentation of the protein (Fig. 5 ).
125I-labeled CH3-Tf was infused through the right internal carotid, and brain fractions were prepared. The volume of distribution of the 1251-labeled CH3-Tf in the brain homogenate was computed from the ratio of dpm/g of brain divided by dpm/,l of perfusate and after 5 min was 27 ± 2 ,ullg (mean + SEM, n = 3). The percentage of trichloroacetic acidprecipitable radioactivity in the perfusate and postvascular supernatant was 90 ± 1% and 77 ± 1%, respectively. The radioactivity from the perfusate and the postvascular supernatant was immunoprecipitated and analyzed by SDS/PAGE (Fig. 5) . The 330-kDa H2L2 form of CH3-Tf and a 250-kDa protein were recovered from the brain (Fig. 5) . The 250-kDa protein appeared to be a breakdown product of the H2L2 form produced by iodination. Both forms bound antigen and protein G, indicating that the fusion proteins cross the BBB as intact molecules and have potential use in brain targeting.
DISCUSSION
The results presented here suggest that Tf can be used as a targeting moiety for the transport of molecules across the BBB and into brain parenchyma. Presumably, transport occurs through an interaction with the TfRs, which are abundant on the brain endothelial cells (30) making up the BBB (31) . The efficient uptake of the Tf fusion proteins is somewhat surprising in that the concentration of Tf in plasma (32) is manyfold higher than the dissociation constant of the BBB TfR (33) . It is possible that the increased brain uptake of the H-Tf and CH3-Tf relative to Tf reflects their interacting with the TfR in a manner different from Tf and may result from the presence of two Tf molecules in the fusion protein. After binding the receptor on the cell surface, Tf is internalized into an acidic compartment where the iron dissociates and the apo-TfR is returned to the cell surface where ligand-receptor dissociation occurs. If the ability of the fusion protein to release iron was altered or if the affinity of the apo-Tf fusion proteins for the receptor at low pH was decreased, mistrafficking of the fusion protein and transport across the BBB may result.
Antibodies to the TfR have been used (13, (34) (35) (36) to deliver low molecular mass drugs (methotrexate), peptides (vasoactive intestinal peptide), and proteins (nerve growth factor) to the brain. By using the anti-TfR antibody, 0.4-0.5% of the injected dose accumulated in the brain parenchyma. This value is only slightly higher than the value observed with H-Tf (=0.3%) but is significantly greater than that observed with either the CH! or CH3 fusion proteins (Fig. 4) . Moreover, the anti-TfR antibody is recovered primarily in the capillary pellet at early times after administration (0-4 hr after injection) and reaches a maximum concentration in the brain parenchyma between 4 Medical Sciences: Shin et al 11 2824 Medical Sciences: Shin et at and 24 hr after injection. In contrast, the Tf fusion proteins never accumulate in the capillary pellet to a significant degree. This difference in the kinetics of uptake most likely relates to the different mechanisms by which these proteins interact with the receptor: the Tf fusion proteins represent modified ligands binding to the ligand binding site on the receptor and like Tf are internalized via the receptor soon after binding (37, 38) , whereas the anti-TfR antibody interacts with an epitope on the TfR distinct from the ligand binding site. Significantly, the uptake of the Tf-antibody fusion proteins was greater than that of the biologically active analgesic drug morphine for which 0.08% of the injected dose per g of rat brain was transported across the BBB (unpublished data).
The intact constant region present in the CH3-Tf may be used to activate immune effector functions. Both complement activation and FcyRI binding require sequences present in CH2 (26, 39 
